a Division of Chest Medicine, Department of Internal Medicine , Hsinchu Mackay Memorial Hospital , Hsinchu , Taiwan.
Hum Vaccin Immunother. 2017 Sep 2;13(9):1960-1971. doi: 10.1080/21645515.2017.1335374. Epub 2017 Jun 12.
Tuberculosis (TB) is a significant cause of illness and death worldwide. Immunotherapy has been investigated in the treatment of TB. The purpose of this study was to perform a meta-analysis investigating the effectiveness of the M. vaccae vaccine. Medline, Cochrane, EMBASE, and Google Scholar were searched until November 5, 2015 using the keywords: tuberculosis, pulmonary TB, therapeutic vaccines, immunotherapy, M. vaccae, sputum smear. Randomized controlled trials (RCTs) or 2-arm prospective studies were included. The primary outcome was the sputum smear clearance rate at 1 or 2 months and 6 months after treatment. Secondary outcomes were improvement of chest X-ray findings, sputum culture negative rate at 1 or 2 months and 6 months, erythrocyte sedimentation rate (ESR), hemoglobin, and leukocyte count, weight gain, and mortality. Of 89 records identified, 13 RCTs were included in the meta-analysis. The number of patients ranged from 22 to 1337, and the mean age ranged from 26.4 to 44.3 y. Patients treated with M. vaccae were more likely to have negative sputum smear results at 1-2 months (pooled OR = 2.642, 95% CI: 1.623-4.301, P < .001) and at 6 months (pooled OR = 2.111, 95% CI: 1.141-3.908, P = .017), and have a negative sputum culture at 1 or 2 months (pooled OR = 2.660, 95% CI: 1.978-3.578, P < .001). The results of this meta-analysis suggest that M. vaccae immunotherapy may be effective in the treatment of pulmonary TB.
结核病（TB）是全球范围内导致发病和死亡的重要原因。免疫疗法已被用于治疗结核病。本研究旨在进行荟萃分析，以调查 M. vaccae 疫苗的有效性。我们使用“tuberculosis”“pulmonary TB”“therapeutic vaccines”“immunotherapy”“M. vaccae”和“sputum smear”等关键词，检索了 Medline、Cochrane、EMBASE 和 Google Scholar 数据库，检索时间截至 2015 年 11 月 5 日。纳入了随机对照试验（RCT）或 2 臂前瞻性研究。主要结局是治疗后 1 或 2 个月和 6 个月时的痰涂片清除率。次要结局是胸部 X 线检查结果的改善、1 或 2 个月和 6 个月时的痰培养阴性率、红细胞沉降率（ESR）、血红蛋白和白细胞计数、体重增加和死亡率。在确定的 89 份记录中，有 13 项 RCT 被纳入荟萃分析。患者人数从 22 到 1337 不等，平均年龄从 26.4 到 44.3 岁。接受 M. vaccae 治疗的患者在 1-2 个月时（合并 OR = 2.642，95% CI：1.623-4.301，P <.001）和 6 个月时（合并 OR = 2.111，95% CI：1.141-3.908，P =.017）获得阴性痰涂片结果的可能性更大，并且在 1 或 2 个月时获得阴性痰培养结果的可能性更大（合并 OR = 2.660，95% CI：1.978-3.578，P <.001）。本荟萃分析的结果表明，M. vaccae 免疫疗法可能对治疗肺结核有效。
